Patrys Limited (ASX:PAB)
Australia · Delayed Price · Currency is AUD 0.0340
0.00 (0.00%)
Sep 18, 2026, 3:29 PM AEST
Patrys Revenue
In the fiscal year ending June 30, 2026, Patrys had annual revenue of 8.99K AUD, down -98.92%. Patrys had revenue of 6.69K in the half year ending June 30, 2026, a decrease of -99.08%.
Revenue
8.99K
Revenue Growth
-98.92%
P/S Ratio
2,553.67
Revenue / Employee
898.50
Employees
10
Market Cap
22.94M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 8.99K | -819.56K | -98.92% |
| Jun 30, 2025 | 828.54K | -565.62K | -40.57% |
| Jun 30, 2024 | 1.39M | -1.46M | -51.11% |
| Jun 30, 2023 | 2.85M | -481.67K | -14.45% |
| Jun 30, 2022 | 3.33M | 2.00M | 149.08% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Radiopharm Theranostics | 13.50M |
| Immuron | 7.71M |
| Argenica Therapeutics | 5.48M |
| Neurotech International | 4.73M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
| Noxopharm | 1.43M |